William Blair Reaffirms “Outperform” Rating for Exagen (NASDAQ:XGN)

Exagen (NASDAQ:XGN)‘s stock had its “outperform” rating restated by equities researchers at William Blair in a report released on Wednesday,RTT News reports. William Blair also issued estimates for Exagen’s FY2026 earnings at ($0.23) EPS.

A number of other research analysts also recently commented on XGN. Canaccord Genuity Group increased their target price on Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 target price on shares of Exagen in a research report on Monday, January 13th.

Exagen Price Performance

XGN stock opened at $3.35 on Wednesday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05. Exagen has a 1 year low of $1.30 and a 1 year high of $6.22. The firm has a market cap of $59.08 million, a P/E ratio of -3.56 and a beta of 1.40. The stock has a 50-day simple moving average of $3.78 and a 200-day simple moving average of $3.57.

Institutional Trading of Exagen

Hedge funds and other institutional investors have recently modified their holdings of the business. Toronto Dominion Bank acquired a new stake in Exagen during the fourth quarter valued at $3,655,000. Driehaus Capital Management LLC bought a new stake in shares of Exagen in the 4th quarter valued at approximately $1,716,000. Northern Trust Corp grew its position in Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after acquiring an additional 2,630 shares during the last quarter. Marshall Wace LLP bought a new stake in Exagen during the 4th quarter worth approximately $66,000. Finally, Kennedy Capital Management LLC boosted its position in Exagen by 8.8% in the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company’s stock valued at $756,000 after buying an additional 14,920 shares during the last quarter. Institutional investors and hedge funds own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).